PhaseRx Inc PZRXQ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.00
- Bid/Ask
- $0.00 / $0.02
- Market Cap
- $2,338.07
- Volume/Avg
- 253 / 287
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 21
- Website
- http://www.phaserx.com
Valuation
|
Metric
|
PZRXQ
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PZRXQ
|
|---|---|
Quick Ratio | 1.93 |
Current Ratio | 2.14 |
Interest Coverage | −13.83 |
Quick Ratio
PZRXQ
Profitability
|
Metric
|
PZRXQ
|
|---|---|
Return on Assets (Normalized) | −99.85% |
Return on Equity (Normalized) | −218.49% |
Return on Invested Capital (Normalized) | −103.32% |
Return on Assets
PZRXQ
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pzxvzhprj | Gfw | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vfwxvdkf | Nzxks | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nrwmwcqn | Xmmtgm | $97.8 Bil | |
MRNA
| Moderna Inc | Vkhxskq | Nclyg | $38.8 Bil | |
ARGX
| argenx SE ADR | Wmhrfyz | Hql | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Mrrxswvt | Xbr | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zyfwkgn | Ckkjc | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bqsndtf | Yjwnxy | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xnwphxfq | Rxlgz | $12.5 Bil | |
INCY
| Incyte Corp | Qmbngkbmh | Xmfwwkk | $11.5 Bil |